BTIG analyst Julian Harrison initiated coverage of MoonLake Immunotherapeutics with a Buy rating and $36 price target. The analyst sees the company’s sonelokimab as well-positioned to emerge as the best-in-class IL-17 inhibitor. Lower molecular weight and albumin binding confer PK advantages will likely drive more efficacy, the analyst tells investors in a research note. The firm says current market leaders in the IL-17 space represent over $7B in annual worldwide revenue yet still leave substantial efficacy on the table by way of suboptimal PK and limited target engagement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MLTX:
- MoonLake initiated with an Overweight at Cantor Fitzgerald
- MoonLake completes patient enrollment in Phase 2 trial of Nanobody sonelokimab
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa
- MoonLake Immunotherapeutics initiated with a Buy at Bryan Garnier